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Summary
Sirtuin 2 (SIRT2) is a member of a family of NAD+-dependent
histone deacetylases (HDAC) that play diverse roles in cellular
metabolism and especially for aging process. SIRT2 is located in
the nucleus, cytoplasm, and mitochondria, is highly expressed in
the central nervous system (CNS), and has been reported to
regulate a variety of processes including oxidative stress, genome
integrity, andmyelination. However, little is known about the role
of SIRT2 in the nervous system specifically during aging. Here, we
show that middle-aged, 13-month-old mice lacking SIRT2 exhibit
locomotor dysfunction due to axonal degeneration, which was
not present in young SIRT2 mice. In addition, these Sirt2/ mice
exhibit mitochondrial depletion resulting in energy failure, and
redox dyshomeostasis. Our results provide a novel link between
SIRT2 and physiological aging impacting the axonal compartment
of the central nervous system, while supporting a major role for
SIRT2 in orchestrating its metabolic regulation. This underscores
the value of SIRT2 as a therapeutic target in the most prevalent
neurodegenerative diseases that undergo with axonal degener-
ation associated with redox and energetic dyshomeostasis.
Key words: aging; axonal degeneration; mitochondria; re-
dox dyshomeostasis; sirtuin.
Introduction
Age-related neurodegenerative diseases are a large group of debilitating
pathologies that includes Alzheimer’s disease (AD), Parkinson’s disease
(PD), Huntington’s disease (HD), and multiple sclerosis (MS). They are
characterized by progressive neuronal degeneration, which leads to cell
death (McSharry, 2010). Many of these diseases share common
pathogenetic mechanisms, including axonal degeneration, which could
be responsible for many of the associated motor and cognitive
dysfunctions. Other common characteristics underlying many age-
related, multifactorial neurodegenerative diseases are chronic impair-
ment of bioenergetics and mitochondria metabolism, together with
redox dyshomeostasis, which cause defects in protein degradation and
inflammation (Lin & Beal, 2006; McWilliams & Ganley, 2016).
Many of the neurodegenerative processes in these disorders have been
linked with sirtuin family members (SIRTs) (Donmez & Outeiro, 2013;
Morris, 2013). SIRTs, or silent information regulator 2 (Sir2) proteins, are a
class of proteins that possess NAD+-dependent deacetylase activity or
ADP-ribosyltransferase activity and play key roles in metabolic adaptive
responses. In mammals, among the seven members of the SIRT family
(SIRT1–SIRT7), SIRT1 has been the most extensively characterized (Hall
et al., 2013). SIRTs have different tissue and subcellular localizations
(Morris, 2013): SIRT1 and SIRT2 are both localized in the nucleus and
cytoplasm; however, SIRT1 is mainly nuclear, whereas SIRT2 is predom-
inantly cytoplasmic. Very recently, it has also been demonstrated that
SIRT2 can be located in the inner mitochondrial membrane (Liu et al.,
2017). SIRT3, SIRT4, and SIRT5 are alsomitochondrial proteins,while SIRT6
and SIRT7 are localized in the nucleus. The distinct cellular distributions of
the SIRT proteins reflect specialized functions in cellular metabolism
(Morris, 2013). For instance, SIRT2 is the most abundant member of the
SIRT family in the central nervous system (CNS) (Zhu et al., 2012), and its
role in these organs has been linked to the regulation of several processes
including the oxidative stress response, metabolism, cell differentiation,
and mitophagy (Donmez & Outeiro, 2013; Liu et al., 2017).
In the CNS, SIRT2 has been shown to play a role in oligodendroglial
cell differentiation and myelination (Werner et al., 2007; Beirowski
et al., 2011; Ji et al., 2011; Zhu et al., 2012). Mice with SIRT2 ablation
specifically in Schwann cells displayed a transient delay of myelination
both during development and after nerve injury (Beirowski et al., 2011).
However, whether SIRT2 also impacts axonal degeneration was not
analyzed in these mice.
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SIRT2 has also been proposed to play a role in neuroinflammation,
although this has been controversial. For example, upon inhibition or
deletion of SIRT2, stimulation of the immune response by lipopolysac-
charide (LPS) led to an overt production of pro-inflammatory cytokines in
an experimental model of colitis and after traumatic brain injury (Lo
Sasso et al., 2015; Yuan et al., 2016), suggesting a role for SIRT2 in
inhibiting the inflammatory response. However, a role for SIRT2 in
promoting inflammation was found upon LPS treatment in microglial cell
lines, macrophages, and mouse brain (Lee et al., 2014; Chen et al.,
2015a; Wang et al., 2016). This was also supported by the observed
attenuation of cytokine levels in a lethal septic model where the activity
of SIRT2 was pharmacologically reduced (Zhao et al., 2015). However,
ischemic brains of WT and Sirt2/ mice were characterized by a similar
induction of neutrophils and activated microglia/macrophages (Krey
et al., 2015). Thus, whether and how SIRT2 regulates inflammation in
the brain remains unclear.
In addition, several studies have identified a major role for SIRT2 in
neurodegeneration (Donmez & Outeiro, 2013; Morris, 2013). Pharma-
cological and/or genetic inhibition of SIRT2 improves disease pathology
in models of AD (Silva et al., 2016), HD (Luthi-Carter et al., 2010), PD,
and cerebral ischemia, but not in models of the motor neuron disease
amyotrophic lateral sclerosis (ALS) (Chen et al., 2015b). However, some
conflicting results have also emerged in HD, for instance, when lack of
SIRT2 had no effect on disease progression specifically in the R6/2 mouse
model (Bobrowska et al., 2012).
Although these studies indicate that SIRT2 has a major role in the
brain, to date there has been no link between SIRT2 and phenotypes
related to axonal degeneration or impaired behavioral or cognitive skills
in middle-aged mice. To address this, we here characterize 13-month-
old Sirt2/ mice at baseline, performing general behavior experiments
(i.e., locomotor tests, circadian activity, anxiety, and cognition), tested
immunohistopathological markers of axonal degeneration, and per-
formed biochemical analyses. We discover that ablation of SIRT2 results
in axonal degeneration, which was associated with locomotor disability,
redox imbalance, and energetic failure. No systemic neuroinflammation
or metabolic syndrome was observed. These results suggest that SIRT2
may constitute a valuable therapeutic target in major neurodegenerative
diseases associated with aging, which manifest with axonopathy caused
by redox and energy metabolism.
Results
Several studies have revealed a key role for SIRT2 in neurodegenerative
(Donmez & Outeiro, 2013) and myelination processes (Werner et al.,
2007; Beirowski et al., 2011; Ji et al., 2011; Zhu et al., 2012). Primary
perturbation of myelinating glial cells has often been linked to profound
secondary effects on axonal function. Axonal malfunction is associated
with axonal degeneration, which is a common feature and main
contributor to incapacity in many neurological diseases such as AD, PD,
HD, MS, or adrenomyeloneuropathy (AMN) as well as of aging (Lin &
Beal, 2006; Ferrer et al., 2010; Galea et al., 2012; McWilliams & Ganley,
2016). Therefore, we analyzed whether Sirt2/ mice develop axonal
degeneration in middle-aged mice (13 months of age).
Sirt2/ mice present axonal degeneration at 13 months of
age
We performed immunohistochemistry on spinal cord from middle-aged
Sirt2/ mice. Sirt2/ mice presented an overt neuropathological
phenotype at 13 months of age characterized by axonal damage
revealed by the accumulation of synaptophysin and RT97 in axonal
swellings (Fig. 1A–D and K). However, this axonal degeneration was not
associated with neuroinflammation in the form of astrocytosis and
microgliosis or macrophage infiltration, as revealed by GFAP, Iba-1, and
CD68 staining, respectively (Fig. 1E–J; Morato et al., 2015). To support
these data, we quantified the expression levels of several cytokines,
chemokines, and their receptors in the spinal cord of Sirt2/ mice. The
absence of neuroinflammation in Sirt2/ mice was consistent with the
lack of induction of several pro-inflammatory molecules as well as the
absence of repression of anti-inflammatory genes. Specifically, genes
involved in both the canonical and noncanonical NFjB pathway (Nfjb1
and Nfjb2, respectively) and in the IKK complex (Ikbkb), which activates
these two pathways, were not dysregulated (Fig. 1L). Our results are the
first to analyze the effects on neuroinflammation of SIRT2 at baseline, in
the absence of a specific immunological stimulus, and in aging mice.
Along with other recently published results (Lee et al., 2014; Chen et al.,
2015a; Krey et al., 2015; Lo Sasso et al., 2015; Zhao et al., 2015; Wang
et al., 2016; Yuan et al., 2016), our results support a strongly context-
dependent and/or indirect role for SIRT2 in the inflammatory response.
Sirt2/ mice exhibit locomotor deficits at 13 months of age
To determine whether the observed axonal degeneration could impact
locomotor function, we assessed the performance of Sirt2/ mice on
the treadmill and bar-cross tests (Morato et al., 2015) at 3.5 and
13 months of age. In the treadmill test, where the mice are evaluated by
their ability to remain on a moving treadmill, only the oldest Sirt2/
mice showed a significant locomotor deficit compared to the littermate
WT mice (Fig. 2A). There was no difference between the young (3.5 m)
Sirt2/ and WT mice. Also in the bar-cross experiments, only the 13-
month-old Sirt2/ mice failed to maintain their balance while walking
across the bar, and displayed a greater tendency to slip off the bar than
age-matched WT mice (Fig. 2B). Thus, Sirt2/ mice exhibit locomotor
disability at 13 but not 3.5 months of age (Fig. 2).
We next performed a general behavioral characterization of middle-
aged Sirt2/ mice by measuring muscle tone and pain sensitivity (grip
strength and hot plate test, respectively), circadian activity, emotional
reactivity or anxiety-like behavior (elevated plus-maze), and cognition
(avoidance learning and novel object recognition). No differences were
observed between 13-month-old Sirt2/ mice and control littermates
(Figs S1–S3).
Together, our results provide evidences for a role of SIRT2 in axonal
degeneration associated with locomotor dysfunction in these mice.
Redox imbalance in spinal cord from Sirt2/ mice
Chronic metabolic impairment and oxidative stress are associated with
the pathogenesis of axonal dysfunction in a growing number of
neurodegenerative diseases including AD, PD, HD, ALS, AMN, and
multiple sclerosis (Lin & Beal, 2006; Ferrer et al., 2010; Galea et al.,
2012). To determine whether the axonal degeneration we observed in
Sirt2/ mice was caused by oxidative stress, we quantified several
protein oxidative damage markers including glutamic semialdehyde
(GSA) and aminoadipic semialdehyde (AASA) for protein carbonylation,
Ne-(carboxymethyl)-lysine (CML) and Ne-(carboxyethyl)-lysine (CEL) for
glycoxidation, and Ne-(malondialdehyde)-lysine (MDAL) for lipoxidation
(Fourcade et al., 2008) (Fig. 3A). We also analyzed reduced glutathione
(GSH), which is the main antioxidant molecule in the cell (Fig. 3B). We
found increased oxidative damage characterized by higher levels of
AASA and MDAL and low level of GSH in spinal cord from 13-month-old
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Sirt2/ mice compared with control littermates. Further, we measured
expression levels of the classical antioxidant enzymes, superoxide
dismutase 1 and 2 (Sod1 and Sod2), glutathione peroxidase 1 (Gpx1),
and catalase (Cat), which encode for key enzymes that reduce oxidative
stress in cells. mRNA levels of Sod1, Sod2, Gpx1, and Cat were
unchanged in middle-aged spinal cord from Sirt2/ mice (Fig. 3C). This
indicates that in the absence of SIRT2, the endogenous antioxidant
defense is blunted, causing rising oxidative damage in these mice, which
may lead to the observed axonal dysfunction.
mtDNA depletion and energy failure in Sirt2/ mice
To study the global consequences of altered redox status, and because









Fig. 1 Sirt2/ mice present axonal degeneration but no neuroinflammation at 13 months of age. Longitudinal and transversal sections of the dorsal spinal cord in WT (A,
C, E, G, I) and Sirt2/ mice (B, D, F, H, J) at 13 months of age (n = 5/genotype) processed for synaptophysin (A–B), RT97 (C–D), Iba-1 (E–F), GFAP (G-H), and CD68 (I-J).
Arrows indicate synaptophysin (A–B) and RT97 (C–D) accumulation in axonal swellings. Small stars indicate Iba-1+ cells (E-F) and GFAP+ cells (G-H). Scale bar = 25 lm. (K)
Quantification of synaptophysin and RT97 accumulation in axonal swellings in 1-cm-long longitudinal sections of the dorsal spinal cord in WT and Sirt2/ mice. The number
of abnormal specific profiles was counted at every 10 sections for each stain. At least three sections corresponding to the dorsal columns of the spinal cord were analyzed per
animal and per stain. (L) Relative mRNA levels of Nfjb1, Nfjb2, Ikbkb, Tnfa, Il1b, Il6, Cxcl10, Cxcl5, Mif, Tnfrs1a, Ccl5, Ccr6, Cxcl12, Tgfb1, iNos, Igf1, Mrc1, Chi3 l3, Il5,
Arg1, and Fizz1 in spinal cord from WT and Sirt2/ mice at 13 months of age (n = 8/genotype). Data represent mean  SD. Statistical analysis was carried out with
Student’s t-test (*P ≤ 0.05, **P ≤ 0.01).
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quantified mtDNA levels as well as ATP, NAD+, and NADH levels in
Sirt2/ mice. We have observed no SIRT2 protein expression in spinal
cord from Sirt2/ mice, which validates that this model is a true
knockout of SIRT2 (Fig. 4A). MtDNA levels were lower in both spinal
cord and cortex of Sirt2/ mice at 13 months compared to control
littermates (Fig. 4B). Of note, this depletion did not appear to be
mediated by the main master regulator of mitochondrial biogenesis Pgc-
1a and its targets Tfam and Nrf1 (Scarpulla et al., 2011) as their
expression levels did not vary (Fig. 4B), although we cannot rule out
other means of controlling Sirt2 expression. We also observed an
increase in expression levels of SIRT1 (at both protein and mRNA levels)
in spinal cord (Fig. 4C,D). Because SIRT1 upregulates PGC-1a, this may
be a compensatory mechanism to prevent mitochondrial depletion in the
absence of SIRT2.
We next quantified ATP levels in spinal cord from Sirt2/ mice
(Fig. 4E). ATP levels were significantly reduced in Sirt2/ mice, which
correlated with an increase in the respiratory control ratio (RCR C. I) (ratio:
complex I (C. I) state 2/C. I state 3) (Fig. 4F). Further, we found that NAD+
but not NADH was elevated in spinal cord from Sirt2/ mice (Fig. 4G).
Given that NAD+ is the limiting substrate for sirtuin activities, and Sirt2 is
highly expressed in spinal cord, our results suggests that SIRT2 could be
the main NAD+ consumer in spinal cord from the sirtuin family.
No systemic metabolic syndrome in Sirt2/ mice
Given the observed effect of SIRT2 loss on redox and energy imbalance,
we quantified metabolically relevant parameters in the 13-month-old
Sirt2/ mice, including body and tissue weight, and glucose and insulin
levels in plasma. No differences were observed compared to WT
(Fig. 5A). Similar data have been reported for 3.5-month-old mice
(Belman et al., 2015). To gain further insight into any adipocyte-related
dysregulation, we measured the levels of leptin and adiponectin, which
are the most abundant adipocytokines produced by adipocytes. We
found that adiponectin levels were reduced, whereas leptin was
increased in serum from Sirt2/ mice at 13 months of age with respect
to controls (Fig. 5B). Altogether, these results indicate that both young
and middle-aged Sirt2/ mice do not develop a systemic metabolic
syndrome or insulin resistance at baseline, in spite of the noted
imbalance of adiponectin and leptin levels.
Discussion
SIRT2 and axonal degeneration
In the current study, we revealed for the first time that middle-aged
Sirt2/ mice exhibited axonal degeneration associated with
Fig. 2 Sirt2/ mice exhibit locomotor deficits at 13 months of age. (A) Plotted
are the ratios between the time length of the shocks (time that mice stay on the
electrified grid) and the number of shocks received, over the duration of each test
and (B) bar-cross test in WT and Sirt2/ mice at 3.5 and 13 months of age
(n = 20/genotype). No falls were recorded. Data represent mean  SD. Statistical
analysis was carried out with Student’s t-test (*P ≤ 0.05, **P ≤ 0.01).
Fig. 3 Redox imbalance in spinal cord from Sirt2/ mice. (A) GSA, AASA, CEL,
CML, and MDAL levels and (B) GSH levels and (C) relative mRNA levels of Sod1,
Sod2, Gpx1, and Cat in spinal cord from WT and Sirt2/ mice at 13 months of
age (n = 8/genotype). Data represent mean  SD. Statistical analysis was
carried out with Student’s t-test (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).
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locomotor disability in the absence of cognitive malfunction (Figs 1
and 2, Figs S1–S3). This may suggest a role for SIRT2 in the axonal
degeneration cascade of neurodegenerative disorders of aging such as
MS (McSharry, 2010), ALS (Fischer-Hayes et al., 2013), X-linked
adrenomyeloneuropathy (X-AMN) (Fourcade et al., 2015), or the
hereditary spastic paraplegias (Fink, 2013). This is supported by two
other studies in which SIRT2 was reduced, both in a model of spastic
paraplegia SPG2 (Werner et al., 2007) and in a model of long-term
vitamin E-deficient mice (Fukui et al., 2012). The SPG2 mice lack
proteolipid protein 1 (PLP) and develop axonal degeneration (Griffiths
et al., 1998). Subsequently, PLP was found to be involved in the
transport of SIRT2 and is abundant in myelin of the CNS (Werner
et al., 2007; Zhu et al., 2012). Thereby, the lack of PLP led to
decreased levels of SIRT2 in the brain (Werner et al., 2007). In the
mouse model of vitamin E deficiency, axonal degeneration appeared
in association with reduced SIRT2 levels in several areas of the brain
(cortex, cerebellum, and hippocampus) at 6 months of age. In the
same model, SIRT2 levels were unchanged at 3 months of age, when
no axonal degeneration was observed (Fukui et al., 2012).
SIRT2 and neuroinflammation
No signs of neuroinflammation have been observed at steady-state level
in the spinal cord of middle-aged Sirt2/ mice when using markers of
astrogliosis (GFAP) or microgliosis (Iba-1) (Fig. 1E–H), corroborated by
lack of activation of pro-inflammatory cytokines (Fig. 1L). We believe
that the lack of neuroinflammation could be attributed to a compen-
satory upregulation of SIRT1 in the spinal cords in this model. Indeed, we
have previously reported that genetic or pharmacological induction (by
resveratrol) of SIRT1 suppressed microgliosis and astrogliosis in a mouse
model of X-ALD (Morato et al., 2015).
SIRT2 and redox/energy homeostasis
In the present work, we identified a pro-oxidative status in 13-month-old
Sirt2/ mice based on the levels of nonenzymatic protein damage
markers and the content of general antioxidant defenses (Fig. 3). Thus,
13-month-old Sirt2/ mice did show increased oxidative (AASA) and
lipoxidative (MDAL) damage, with no changes for glycoxidative markers
Fig. 4 mtDNA depletion and energy failure in Sirt2/ mice. (A) SIRT2 protein level in spinal cord from WT and Sirt2/ mice at 13 months of age (n = 6/genotype), (B)
mtDNA levels in spinal cord and cortex (n = 8/genotype), (C) relative mRNA levels of Sirt2, Sirt1, Pgc-1a, Tfam, and Nrf1 in spinal cord and cortex (n = 8/genotype), (D) SIRT1
protein level in spinal cord (n = 6/genotype), (E) ATP levels in spinal cord and cortex (n = 8/genotype), (F) ex vivo mitochondrial respiration analysis performed on
permeabilized sections of spinal cord (n = 5/genotype), and (G) NAD+, NADH, and NAD+/NADH ratio in spinal cord and cortex (n = 8/genotype) from WT and Sirt2/ mice
at 13 months of age. Data represent mean  SD. Statistical analysis was carried out with Student’s t-test (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).
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(CEL and CML), suggesting a preferential type of protein damage, at
least at this age. Surprisingly, we found dissociation between the protein
carbonyls AASA (increased) and GSA (decreased). This discordance could
be ascribed to the residues which act as substrates for its formation: Arg/
Pro residues for GSA and Lys residues for AASA. In this context, the clear
observed divergence for the content of AASA vs. GSA suggests
differences in the proteomic profile of Sirt2/ vs. wild-type mice
leading to the presence of a protein pool which differs in structural and
functional properties (amino acids profile, location in flexible regions,
solvent accessibility, proximity with possible metal ion binding sites)
prone to a specific type of damage. Further studies, probably in the
context of proteomic analysis, are, however, needed to confirm this
hypothesis. Along these lines, lower levels of GSH were detected in
Sirt2/ mice contributing to generate a pro-oxidative status at this age.
The impaired redox status appears not to be restricted to spinal cords, as
Liu et al. showed an increase in the GSSH/GSH ratio in striatum (Liu
et al., 2017). However, this was associated with an overall increased
ratio of GSSG/GSH, which indicates a pro-oxidative status (Liu et al.,
2017). In addition, we showed that SIRT2 regulated energy homeostasis
(ATP content and NAD+ levels) in the CNS of middle-aged Sirt2/ mice
(Fig. 4), which is supported by data for ATP in both young and aged mice
(Liu et al., 2017). A role for SIRT2 in redox status and energy
homeostasis has been suggested in several studies due to its capacity
to regulate the activities of specific transcription factors and metabolic
enzymes. For example, SIRT2 deacetylated and thus activated FOXO3a
and its target genes such as Sod2, which is a key player in endogenous
antioxidant defense. In the absence of SIRT2, SOD2 was not activated
(Wang et al., 2007). In addition, SIRT2 regenerated GSH levels via the
conversion of NADP+ to NADPH, under oxidative stress conditions (Wang
et al., 2014). Regarding NADPH production, SIRT2 has been shown to
deacetylate and thereby activate glucose-6-phosphate dehydrogenase
(G6PD), the first enzyme of the pentose phosphate pathway (PPP) (Wang
et al., 2014), and the glycolytic enzyme phosphoglycerate mutase
(PGAM) (Xu et al., 2014). PGAM regulates NADPH homeostasis because
both substrate (3-phosphoglycerate) and product (2-phosphoglycerate)
are allosteric regulators of the PPP (Hitosugi et al., 2012). In the absence
of SIRT2, G6PD and PGAM were degraded and NADPH levels lowered. In
conclusion, SIRT2 is thought to control the PPP switch, and therefore
NADPH and GSH pools (Wang et al., 2014; Xu et al., 2014).
With respect to energy homeostasis, it has been shown that the
inhibition of SIRT2 in both neuron-like PC12 (Nie et al., 2011) and
microglia BV2 cell lines (Li et al., 2013; Nie et al., 2014) resulted in ATP
reduction followed by cell death. In the absence of SIRT2, we find NAD+
levels increase in spinal cord. As NAD+ is a substrate of poly(ADP-ribose)
polymerase (PARP1) (Rack et al., 2016), we speculate that PARP1 could
be activated in the CNS of Sirt2/ mice. Consistent with this, cell death
in BV2 microglial cell lines after SIRT2 inhibition depended on PARP1
activation (Li et al., 2013).
SIRT2 and the metabolic syndrome
In our study, middle-aged Sirt2/ mice did not develop a systemic
metabolic syndrome/insulin resistance (Fig. 5). This is consistent with
several experiments in young adult Sirt2/ mice: 3.5-month-old Sirt2/
mice had lower blood glucose levels compared with control mice (Belman
et al., 2015). Further, it was demonstrated that SIRT2 regulates PECK1
expression, which is the limiting enzyme for gluconeogenesis. Elevated
gluconeogenesis is associated with type II diabetes. The authors showed
that reduction of SIRT2, using adenovirus containing shRNA against SIRT2
in mice, resulted in degradation of PECK1 in the liver and decreased
glucose levels in the blood (Jiang et al., 2011). However, SIRT2 has been
linked with metabolic syndrome/insulin resistance under different chal-
lenges. Under high-fat conditions, WT mice gained more weight
compared to mice where HIF1a was deleted specifically in white adipose
tissue (WAT), indicating a protective role for HIF1a against obesity. The
underlying molecular mechanism was found to be dependent on SIRT2:
HIF1a bound to the SIRT2 promoter and decreased its expression. Further,
in these Hif1a knockout mice, PGC-1awas not activated by SIRT2, which
decreased mitochondria numbers, energy expenditure, and fatty acid
catabolism. To corroborate this role for HIF1a and SIRT2 in obesity, their
expression levels were quantified in visceral white adipose tissue of human
obese individuals. Consistently, HIF1a was induced, whereas SIRT2 was
reduced in obese patients (Krishnan et al., 2012).
SIRT2 and aging
Aging is defined by nine main hallmarks: genomic instability, telomere
attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient
sensing, mitochondrial dysfunction, cellular senescence, stem cell
exhaustion, and altered intercellular communication (Lopez-Otin et al.,
2016). In the present study, we find that middle-aged Sirt2/ mice
exhibit mitochondrial depletion, redox and energetic imbalance, and
axonal degeneration. Previous work has shown that SIRT2 induces the
checkpoint kinase BubR1 to increase lifespan in mice (North et al.,
2014), and revealed SIRT2 to be a novel marker of cellular senescence
(Anwar et al., 2016). In addition, other studies have linked SIRT2 with
Fig. 5 No metabolic syndrome in Sirt2/ mice. (A) Body and tissue (liver, WAT,
BAT) weight, tissue weight/body weight ratio, and glucose and insulin plasma
levels in WT and Sirt2/ mice at 13 months of age (n = 6/genotype). (B)
Adiponectin, leptin, and leptin/adiponectin ratio in blood from WT and Sirt2/
mice at 13 months of age (n = 6/genotype). Data represent mean  SD. Statistical
analysis was carried out with Student’s t-test (*P ≤ 0.05, **P ≤ 0.01).
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DNA damage and genome instability, epigenetic regulation, and stem
cell differentiation (Serrano et al., 2013; Stein & Imai, 2014). Our data
reinforce the notion of SIRT2 acting as a powerful regulator of aging
with a potential role in neurodegeneration. Indeed, pathology of aging
could appear earlier in rodents (middle-aged) as already observed in
mouse models of several age-related disorders such as AD or ALS.
Materials and methods
Mouse strain
The generation and genotyping of Sirt2/ mice have been previously
described (Serrano et al., 2013). We did not observe SIRT2 protein
expression in spinal cord from Sirt2/ mice (Fig. 4A). The mice used for
the study were of a pure C57BL/6J background. The animals were
sacrificed and the tissues were recovered and stored at 80 °C. All of
the methods employed in this study were in accordance with the Guide
for the Care and Use of Laboratory Animals published by the U.S.
National Institutes of Health (NIH Publications No. 85-23, revised 1996)
and the guidelines of the ethical committees of IDIBELL and the
Generalitat de Catalunya, Spain.
Locomotor tests
Locomotor function was performed in WT and Sirt2/ mice at 3.5 and
13 months of age under blinded conditions as described (Pujol et al.,
2004; Morato et al., 2015).
Circadian activity (CA)
CA was measured using activity cages (TSE, Germany) that consist of
infrared detection photobeams for analysis of horizontal activity. The test
was performed under low-nonaversive lighting conditions (50 lux.) to
avoid stressful stimuli. Total distance travelled each 30 min was recorded
for 24 h. Mice were individually housed in standard Makrolon cages
(40 cm long 9 25 cm wide 9 20 cm high) during 24 h for 2 consec-
utive days.
Muscle tone and pain sensitivity
Grip strength
To assess forelimb and hindlimb strength, mice were held by the tail and
placed on the apparatus so that they grabbed the handle with both front
paws and then were gently pulled back until they released it. Each
session consisted of three trials.
Hot plate
To assess nociception, mice were placed on a hot plate at 52  0.1 °C
surrounded by a plastic cylinder (19 cm diameter, 19 cm high), and
latency to paw licking and jump was manually registered by the
experimenter. Amaximum latencyof 300 swas set to avoid tissuedamage.
Emotional reactivity
To study anxiety-like behavior, mice were placed on an elevated plus-maze
that consisted of a black Plexiglas apparatus with four arms (29 cm
long 9 5 cm wide) set in cross from a neutral square (5 9 5 cm). Two
opposite arms were delimited by vertical walls (closed arms), and the other
two arms had unprotected edges (open arms). The maze was elevated
40 cm above the floor and placed under indirect light (100 lx.). At the
beginning of a 5-min session, each mouse was placed in the central zone,
facing one of the open arms. A video-tracking camera registered time
spent, number of entries, speed, and distance in the different zones.
Cognition
Avoidance learning
This test assessed the formation of recent and long-term memory
(consolidation) using a negative reinforcement, and has strong depen-
dence on the cholinergic system. The passive avoidance paradigms
consist of a circular platform (3 cm diameter) located on the center of an
electrified grid. Mice were placed on the small platform, and when they
stepped down, they received a foot shock (0.6 mA; 2 s). The latency to
step down from the platform was automatically registered by the
apparatus until a maximum of 300 s. On day 1, mice were trained with
the negative reinforcement; 24 h later, they were tested; and 1 week
later, they were retested for avoidance learning.
Novel object recognition
This test evaluates recognition memory for previously explored objects, a
cognitive domain that depends on hippocampal functional integrity.
Novel object recognition was examined in a Y-maze apparatus consisting
of three adjacent arms (each arm is 30 cm 9 5 cm 9 6 cm) delineating
a Y shape, and thus restricting the zone where mice are allowed to
move, increasing the amount of exploration in all groups of mice. The
protocol consisted of three sessions:
1 Habituation session Animals were habituated for 8 min in the Y-
maze. During this habituation session, the number of entries in the
three arms was manually recorded by the experimenter. Moreover,
the percentage of spontaneous alternation was also measured.
Spontaneous alternation was considered when mice consecutively
entered nonpreviously explored arms. The percentage of sponta-
neous alternation was mathematically estimated as the number of
consecutive entrances divided by the maximum alternation (total
number of entries divided by 3) and 9100.
2 Familiarization session Four hours later, mice were placed in the Y-
maze that contained two identical objects, plastic-made, and
located on two of the arm ends. All mice were placed on the end
of the arm that did not contain any object. Time exploring the two
objects was recorded for 8 min.
3 Test session After 24 h, mice will be presented to two objects for
8 min; one will be the same used in the familiarization session and
the other will be a novel one. The discrimination index is calculated
as time exploring the novel object – time exploring the familiar
object/total time of exploration 9 100. The position of the novel
object will be counterbalanced between animals.
The arena and objects were deeply cleaned between animals to avoid
olfactory cues. All measures of exploration were registeredmanually by the
experimenter blind to genotype or treatment. Exploratory behavior is
defined as the animal directing its nose toward the object at a distance of
< 2 cm. Sitting on or resting against the object was not considered as
exploration.
RNA and DNA extraction
Total RNA was extracted using RNeasy Kit (Qiagen) according to the
manufacturer’s instructions. Total DNA was extracted using Gentra
Puregene Tissue Kit (Qiagen) according to the manufacturer’s instructions.
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Quantitative real-time PCR
TaqMan real-timePCRwasperformed in theLightCycler480Real-TimePCR
System (Roche Diagnostics GmbH, Mannheim, Baden-W€urttemberg,
Germany) using the TaqMan Universal PCRmaster mix and the standardized
probes for mouse: Arg1 (Mm00475991_m1), Cat (Mm00437992_m1),
Ccl5 (Mm01302427_m1), Ccr6 (Mm99999114_s1), Chi3 l3/Ym1
(Mm00657889_mH), Cxcl10 (Mm00445235_m1), Cxcl5 (Mm00436451_
m1), Fizz1/Retnla (Mm00445109_m1), Gpx1 (Mm00656767_g1), Ikbkb
(Mm01222247_m1), Il1b (Mm01336189_m1), Il5 (Mm00439646_m1), Il6
(Mm00446190_m1), Mif_LDC (Mm 01611157_gH), Mrc1 (Mm01329362_
m1), Nfkb1 (Mm00476379_m1), Nfkb2 (Mm00479807_m1), Nos2
(Mm00440502_m1), Nrf-1 (Mm00447996), Pgc-1a (Mm00447183_m1),
Sirt1 (Mm00490758_m1), Sod1 (Mm01700393_g1), Sod2 (Mm00449726_
m1) Tfam (Mm00447485), Tgfb1 (Mm01178820_m1), Tnfa (Mm00443258_
m1), and Tnfrsf1 (Mm01182929_m1). To quantify mouse mtDNA content,
mouse cytochrome b (cytb) probe has been designed (Custom TaqMan Gene
Expression Assays; Applied Biosystems). The sequences for mouse cytb were
ATGACCCCAATACGCAAAATTA (forward) and GGAGGACATAGCCTAT-
GAAGG (reverse), and the FAM-labeled probe was TTGCAACTATAGCAA-
CAG.Quantification ofmtDNAwas referred to nuclear DNAas determined by
theamplificationof themouse intronlessnucleargeneC/EBPa (Mm00514283).
Expression of the genes of interest was normalized to that of the reference
controlmouseRpl0 (Mm01974474_gH).Eachsamplewasruninduplicate,and
the mean value of the duplicate was used to calculate the mtDNA amount or
mRNA expression using the comparative (2DCt) method, according to the
manufacturer’s instructions (Morato et al., 2015).
Glucose, insulin, leptin, and adiponectin levels
Glucose was measured in blood using the OneTouch Ultra Easy glucose
meter. Insulin, leptin, and adiponectin were quantified in plasma with
ELISA kits from BioVendor (RAI005R, #RD291001200R, #RD293023100R)
according to the manufacturer’s instructions.
GSH levels, NAD+/NADH determination, and ATP levels
The reduced glutathione (GSH) levels were determined by LC-ESI-qTOF-
MS as previously described (Morato et al., 2015). NAD+/NADH levels
were measured by the NAD cycling assay. The ATP levels were measured
by a chemiluminescence system using ATPlite 1step (Perkin Elmer)
(Morato et al., 2015).
Measurement of GSA (glutamic semialdehyde), AASA
(aminoadipic semialdehyde), CEL (N2-(carboxyethyl)-lysine),
CML (N2-(carboxymethyl)-lysine), and MDAL
(N2-malondialdehyde-lysine)
GSA, AASA, CEL, CML, and MDAL concentrations in total proteins from
spinal cord homogenates were measured by gas chromatography/mass
spectrometry (GC/MS) (Fourcade et al., 2008). The product levels were
expressed as the ratio of micromoles of GSA, AASA, CEL, CML, or MDAL
to 1 mole of lysine.
Immunoblot analysis
Tissue samples were lysed in ice-cold RIPA buffer (50 mM Tris–HCl, pH 8,
12 mM deoxycholic acid, 150 mM NaCl, and 1% NP-40, supplemented
with Complete Protease Inhibitor Cocktail (Roche) and Phosphatase
Inhibitor Cocktail ‘PhosSTOP EASYpack’ (Roche)) using a Teflon-on-glass
homogenizer and then centrifuged at 1500 g for 10 min at 4 °C. The
protein concentration was determined using a BCA protein assay kit
(Thermo Fisher Scientific, Inc., Waltham, Massachusetts, USA). Samples
were boiled for 5 min in Laemmli’s buffer and run on Bis-Tris gels. After
electrophoresis, proteins were transferred to nitrocellulose membranes
using the iBlot 2 Dry blotting system (Life Technologies, Waltham,
Massachusetts, USA) and then have been blocked in 5% bovine serum
albumin (BSA, Sigma-Aldrich, St. Louis, Missouri, USA) in 0.05% TBS-
Tween (TBS-T) for 1 h at room temperature. Next, membranes have been
incubated with appropriate primary antibodies (SIRT1 (Abcam, ab12193,
Cambridge, Massachusetts, USA), pyruvate kinase (Abcam, ab38237,
Cambridge, Massachusetts, USA), SIRT2 (Cell Signaling Technology,
2313, Danvers, Massachusetts, USA), and c-tubulin (clone GTU-88,
Sigma, T6557)) in 5% BSA in 0.05% TBS-T overnight at 4 °C. Following
incubation with diluted secondary antibodies (anti-mouse IgG linked to
horseradish peroxidase (DAKO, P0447, Santa Clara, California, USA),
anti-rabbit IgG linked to horseradish peroxidase (DAKO, P0448, Santa
Clara, California, USA) in 0.05% TBS-T for 1 h at room temperature,
proteins were visualized with an enhanced chemiluminescence Western
blot detection system (GE Healthcare Bio-Sciences AB using the
ChemiDocTM Touch Gel Imaging System (Bio-Rad Laboratories, Inc.,
Hercules, California, USA). Immunoblots were quantified using Image Lab
software (Bio-Rad Laboratories, Inc., Hercules, California, USA).
High-resolution respirometry
High-resolution respirometry was performed as previously described
(Morato et al., 2015).
Immunohistochemistry
Spinal cordswereharvested from13-month-oldWTandSirt2/mice, after
perfusion with PFA 4%, basically as described (Morato et al., 2015). Spinal
cords were embedded in paraffin, and serial sections (5 lm thick) were cut
in a transversal or longitudinal (1-cm-long) plane. The number of abnormal
specific profiles was counted at every 10 sections for each stain. At least
three sections corresponding to the dorsal columns of the spinal cord were
analyzed per animal and per stain. The sections were stained with
hematoxylin and eosin and Sudan black, or processed for immunohisto-
chemistry using glial fibrillary acidic protein (GFAP) [Dako, rabbit polyclonal,
1:500, Santa Clara, California, USA], synaptophysin [Dako, monoclonal,
1:500, Santa Clara, California, USA], CD68 [Abcam, rabbit polyclonal,
1:500, Cambridge, Massachusetts, USA], and RT97 [Boehringer, rabbit
polyclonal, 1:500]; andwith Iba-1 [Wako, rabbit polyclonal, 1:1000] usedas
a marker of microglial cells. The results were expressed as the mean  s-
tandard deviation.
Statistical analysis
The data are presented as mean  standard deviation (SD) or standard
error of the mean (SEM). Significant differences were determined by
Student’s t-test or repeated-measures ANOVA to measure circadian
activity (*P < 0.05, **P < 0.01, ***P < 0.001) after verifying normality.
Statistical analyses were performed using the software program SPSS 12.0.
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